Highlights:

  • Patrys raises A$3.2 million via placement to strengthen balance sheet
  • Funding to support Phase 1A clinical trial and FDA pre-IND preparation
  • Strong investor demand reflects confidence in delirium treatment program

Patrys Limited (ASX:PAB) has secured firm commitments to raise approximately A$3.2 million through a share placement, reinforcing its financial position and enabling progress toward clinical trials. The placement, priced at A$0.024 per share, attracted solid participation from both new and existing investors despite challenging market conditions. The capital raise marks a significant milestone as the company advances its therapeutic program targeting delirium, an area with substantial unmet medical need. Proceeds will be directed toward initiating a Phase 1A clinical trial, a key step required for its pre-IND submission to the U.S. Food and Drug Administration.

Additional funds will support manufacturing readiness, regulatory engagement, and intellectual property development. Overall, the funding strengthens Patrys’ ability to execute near-term milestones and positions the company for further clinical and regulatory progress.

How Will the Funds Support Clinical Development?

The funds raised will primarily be used to advance Patrys Limited’s clinical development program, with a strong focus on initiating its first-in-human Phase 1A trial. This step is critical for progressing toward regulatory approval pathways and will support the company’s pre-IND engagement with the U.S. Food and Drug Administration. Capital will also be allocated toward manufacturing activities to ensure the drug candidate is ready for clinical use.

In addition, Patrys plans to engage specialist consultants and prepare detailed regulatory documentation to establish a clear development roadmap. These activities are essential for reducing execution risk and accelerating the transition from preclinical to clinical stages, ultimately bringing the company closer to commercialisation opportunities.

What Are the Key Terms and Investor Participation?

The placement involves issuing new shares at A$0.024 each, representing a discount to the recent trading average, along with one free attaching option for every four shares subscribed. These options are exercisable at A$0.048 and valid until November 2030, subject to shareholder approval. The offering was supported by both institutional and strategic investors, highlighting confidence in the company’s direction.

Templar Corporate Pty Ltd acted as the lead manager for the transaction. Additionally, company directors have indicated their intention to participate by investing A$160,000, pending shareholder approval. The structure of the raise balances immediate capital needs with longer-term investor incentives, while maintaining flexibility for future funding initiatives.